Substance Use Stigma and Vaccine Hesitancy: Whose Beliefs Did the Survey Measure?

A survey linked negative public attitudes toward people with certain substance-use disorders to COVID-19 vaccine hesitancy. The study did not ask whether people using methamphetamine experienced stigma that caused them to avoid vaccination. Its central measurement was the respondent’s stigmatizing attitude toward other people.

Whose attitudes were measured?

Powell and colleagues analyzed responses from 6,515 adults in an October-November 2021 AmeriSpeak survey. AmeriSpeak is a probability-based household panel. The study was cross-sectional: attitudes, vaccine intentions and other information were collected for the same survey period.

The substance-use scales asked about willingness to work with someone or have that person marry into the family, perceptions of stealing or workplace risk, dangerousness and trustworthiness. Items addressed people described as having a past or current substance-use disorder. Higher scores indicated greater stigma. Separate scales concerned opioids, methamphetamine, cocaine and alcohol.

Hesitancy combined several different answers

Respondents who had already been vaccinated or planned vaccination as soon as possible were classified as not hesitant. The hesitant group combined people planning to wait for more evidence, people saying they would not be vaccinated and people who were unsure.

That combined outcome is broader than refusal. A reported association with hesitancy cannot be restated as an association specifically with permanent refusal, verified failure to receive a dose, or an individual’s future behavior. The definition used in the analysis determines what its result means.

The associations were adjusted group estimates

The reported adjusted odds ratios relating the respective stigma measures to hesitancy were 1.34 for opioids, 1.40 for methamphetamine and 1.28 for cocaine; these associations met the paper’s significance criteria. The alcohol estimate was 1.06 and was not statistically significant.

An odds ratio is not a percentage-point increase in probability. These estimates also describe associations for the scales as modeled, rather than a diagnosis applicable to every person with a particular belief. The models included other demographic and attitudinal information, but adjustment does not establish that all alternative explanations were measured.

Reliability does not establish causation or prediction

The authors reported good internal consistency for the stigma scales. That supports consistency among their component items. It does not prove that stigma causes vaccine hesitancy, that changing one attitude changes the other, or that a scale accurately predicts later vaccination in new individuals.

The paper notes self-report and social-desirability concerns, unmeasured prior COVID-19 infection, and possible nonresponse bias. About 40% of contacted panel members completed this project’s survey; weighting addressed observed demographic differences but cannot guarantee removal of every response bias.

Keep the direction of the question intact

The finding concerns public attitudes toward people with substance-use disorders and the same respondents’ vaccine hesitancy. It should not be transformed into a claim about the vaccine beliefs of all people who use drugs, nor used to characterize an individual patient’s motives. The study offers an exploratory association that may guide additional research, while leaving the causal pathway and intervention effects open.

Scientific source

Powell N, Taylor B, Hotton A, and colleagues. The Relationship between Substance Use Stigma and COVID-19 Vaccine Hesitancy. Vaccines. 2023;11:1194. DOI: 10.3390/vaccines11071194. This analysis uses the supplied historical survey, without treating its 2021 responses as current population estimates.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

Why Trace Opioid Detection Is Different From a Verified Adulterated Dose

Short answer: Detecting an unexpected opioid at trace level does not, by itself, establish that a product contained an active adulterating dose. In a British Columbia drug-checking study, 189 of 8,889 samples not expected to include fentanyl had an unexpected opioid, and 61.4% of those detections were at trace concentration….

Spread the love

Read Article: Why Trace Opioid Detection Is Different From a Verified Adulterated Dose

Were Nitazenes Present in Most Ontario Opioid Deaths? Read the 79-of-8,719 Denominator

Short answer: No. In coroner data analyzed for a Canadian study, nitazenes were present in 79 of 8,719 Ontario opioid deaths (0.91%) from January 2019 through December 2022. The Toronto subset was 33 of 1,803 opioid deaths (1.83%). These are presence counts in specified death records, not evidence that nitazenes…

Spread the love

Read Article: Were Nitazenes Present in Most Ontario Opioid Deaths? Read the 79-of-8,719 Denominator

Why a GHB Result May Not Identify the Substance Originally Taken

Short answer: A test that reports GHB does not necessarily identify the substance a person originally took. A scientific review by Busardò and Jones explains that gamma-butyrolactone (GBL) and 1,4-butanediol can convert rapidly to GHB after ingestion. The measured GHB is a real analytical finding, but the starting compound is…

Spread the love

Read Article: Why a GHB Result May Not Identify the Substance Originally Taken

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us